‘We are very happy to possess entered into this contract with Logista Pharma to distribute BRINAVESS to your Spanish customers,’ stated Karim Lalji, Cardiome's Chief Business Officer. Spain is a key growth marketplace for BRINAVESS and our new romantic relationship with Logista Pharma is among the many steps towards creating a effective brand in this country.’ The state-of-the-art processes developed by Logista Pharma will ensure secure and timely fulfillment of BRINAVESS orders to all or any our hospital customers. Financial details of the agreement weren’t disclosed.. Cardiome enters into contract with Logista to distribute BRINAVESS within Spanish market Cardiome Pharma Corp.As previously disclosed, the payment has been made in connection with the growth of the diabetes alliance between AstraZeneca and Bristol-Myers Squibb to include the development and advertising of Amylin’s portfolio of diabetes items, and income and losses due to the collaboration will be shared equally. The right to exercise this option can be effective once applicable anti-trust and competition approvals are received by AstraZeneca. Upon the workout of the option an additional payment of $135 million will be made to Bristol-Myers Squibb. The completion of our acquisition of Amylin and the growth of our diabetes alliance with AstraZeneca will increase and strengthen our innovative portfolio of diabetes medicines, extending its reach over the spectrum of treatment plans, said Lamberto Andreotti, ceo, Bristol-Myers Squibb.